Akumin (TSX:AKU) EBITDA Margin % : -15.92% (As of Sep. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Akumin EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Akumin's EBITDA for the three months ended in Sep. 2023 was C$-38.9 Mil. Akumin's Revenue for the three months ended in Sep. 2023 was C$244.4 Mil. Therefore, Akumin's EBITDA margin for the quarter that ended in Sep. 2023 was -15.92%.

Akumin EBITDA Margin % Historical Data

The historical data trend for Akumin's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Akumin EBITDA Margin % Chart

Akumin Annual Data

Trend

Sep15

Sep16

Sep17

Dec18

Dec19

Dec20

Dec21

Dec22

EBITDA Margin %

Get a 7-Day Free Trial

14.13

9.12

6.61

10.04

9.74

Akumin Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
EBITDA Margin %	Get a 7-Day Free Trial															9.14	1.91	13.53	-17.21	-15.92

Competitive Comparison of Akumin's EBITDA Margin %

For the Diagnostics & Research subindustry, Akumin's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Akumin's EBITDA Margin % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Akumin's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Akumin's EBITDA Margin % falls into.

Akumin EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Akumin's EBITDA Margin % for the fiscal year that ended in Dec. 2022 is calculated as

EBITDA Margin %	=	EBITDA (A: Dec. 2022 )	/	Revenue (A: Dec. 2022 )
	=	99.225	/	1018.374
	=	9.74 %

Akumin's EBITDA Margin % for the quarter that ended in Sep. 2023 is calculated as

EBITDA Margin %	=	EBITDA (Q: Sep. 2023 )	/	Revenue (Q: Sep. 2023 )
	=	-38.917	/	244.402
	=	-15.92 %

Akumin (TSX:AKU) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Akumin EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Akumin's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Akumin (TSX:AKU) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Akumin Inc (TSX:AKU) » Definitions » EBITDA Margin %

Comparable Companies

Traded in Other Exchanges

AKUMQ:USA

Address

8300 West Sunrise Boulevard, Plantation, FL, USA, 33322

Website

https://www.akumin.com

Akumin Inc is a Canada-based company that provides freestanding, fixed-site outpatient diagnostic imaging services in the United States. The company operates in Florida, Pennsylvania, Delaware, Texas, Illinois, and Kansas. It offers physicians with imaging capabilities to facilitate the diagnosis and treatment of diseases and disorders and may reduce unnecessary invasive procedures, minimizing the cost and amount of care for patients. The company's imaging procedures include MRI, CT, positron emission tomography, ultrasound, X-ray, mammography, and other diagnostic or interventional radiology procedures. It operates in two reportable business segments: radiology and oncology. The radiology segment acconts for majority revenue.

Executives

Marcus Quesenberry	Senior Officer
Amy Michelle Adams	Senior Officer

Akumin (TSX:AKU) Headlines

No Headlines